AP NEWS

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 58, 52, 2, 69 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 15, 19, 13, 3 and 1 molecules, respectively.

Key Topics Covered

Introduction Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones Appendix

Companies Mentioned

4SC AG AbbVie Inc Ariad Pharmaceuticals Inc Array BioPharma Inc AstraZeneca Plc Atara Biotherapeutics Inc Bristol-Myers Squibb Co Calithera Biosciences Inc CanBas Co Ltd CARsgen Therapeutics Ltd Cyclacel Pharmaceuticals Inc Daiichi Sankyo Co Ltd Deciphera Pharmaceuticals LLC Eli Lilly and Co Formula Pharmaceuticals Inc Gamida Cell Ltd Gilead Sciences Inc GlaxoSmithKline Plc ImmunoGen Inc Johnson & Johnson Juno Therapeutics Inc NBE-Therapeutics AG Nimbus Therapeutics LLC Nohla Therapeutics Inc Novartis AG OncoTherapy Science Inc Pfenex Inc Pfizer Inc Pharma Mar SA Polyphor Ltd Protheragen Inc Sanofi Sareum Holdings Plc Seattle Genetics Inc Shire Plc

For more information about this report visit https://www.researchandmarkets.com/research/vb74gb/acute_lymphocytic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006358/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Leukemia Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 12:13 PM/DISC: 06/05/2018 12:13 PM

http://www.businesswire.com/news/home/20180605006358/en

AP RADIO
Update hourly